News/Announcements

RFA for new Centers of Excellence for Translational Research.
2013 RCE National Meeting to be held April 7-9 in Seattle.

Recent Publications

Graham RL et al. A stably attenuated coronavirus vaccine platform with impaired replicase fidelity is effective in an aged, immunologically vulnerable animal model. Nature Med. 2012
Messer WB et al. Development and Characterization of a Reverse Genetic System for Studying Dengue Virus Serotype 3 Strain Variation and Neutralization. PLoS Neglected Tropical Diseases. 2012
Napier BA & Weiss DS. A novel link between intraphagosomal boitin requirements and virulence in Francisella. PNAS 2012.
Schneider M et. al (Ting JP). The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-kappaB. Nature Immunol. 2012.

SERCEB Mission

Through our programs in host-pathogen interactions and interventions, SERCEB aims to
discover new therapies and principles by which effective vaccines and other intervention
measures can be developed for diseases and pathogens that threaten the health of our
citizens.

Our cross-institutional research programs focus on alphaviruses and flaviviruses (with an emphasis on dengue), influenza viruses, coronaviruses and virus evolution, Francisella and Y. pestis, and innate and adaptive immunity. SERCEB also supports additional collaborations through internally administered award programs.

Our mission includes emergency response, education and training programs for investigators new to biodefense and emerging infectious disease research, including

SERCEB Diversity Statement